[HTML][HTML] Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
S Karageorgopoulou, ID Kostakis, M Gazouli… - BMC cancer, 2017 - Springer
Background Recognizing resistance or susceptibility to the current standard cisplatin and
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy
S Karageorgopoulou, ID Kostakis, M Gazouli… - BMC …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Recognizing resistance or susceptibility to the current standard cisplatin and
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
[PDF][PDF] Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
S Karageorgopoulou, ID Kostakis, M Gazouli… - 2017 - academia.edu
Background: Recognizing resistance or susceptibility to the current standard cisplatin and
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
[HTML][HTML] Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
S Karageorgopoulou, ID Kostakis, M Gazouli… - BMC Cancer, 2017 - ncbi.nlm.nih.gov
Background Recognizing resistance or susceptibility to the current standard cisplatin and
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
[HTML][HTML] Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
S Karageorgopoulou, ID Kostakis… - BMC …, 2017 - bmccancer.biomedcentral.com
Recognizing resistance or susceptibility to the current standard cisplatin and paclitaxel
treatment could improve therapeutic outcomes of metastatic or recurrent cervical cancer …
treatment could improve therapeutic outcomes of metastatic or recurrent cervical cancer …
Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
S Karageorgopoulou, ID Kostakis, M Gazouli… - BMC …, 2017 - search.proquest.com
Background Recognizing resistance or susceptibility to the current standard cisplatin and
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
S Karageorgopoulou, ID Kostakis, M Gazouli… - BMC Cancer, 2017 - europepmc.org
Background Recognizing resistance or susceptibility to the current standard cisplatin and
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy
S Karageorgopoulou, ID Kostakis, M Gazouli… - BMC Cancer, 2017 - go.gale.com
Background Recognizing resistance or susceptibility to the current standard cisplatin and
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
[PDF][PDF] Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
S Karageorgopoulou, ID Kostakis, M Gazouli… - 2017 - academia.edu
Background: Recognizing resistance or susceptibility to the current standard cisplatin and
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
[PDF][PDF] Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
S Karageorgopoulou, ID Kostakis, M Gazouli… - 2017 - bmccancer.biomedcentral.com
Background: Recognizing resistance or susceptibility to the current standard cisplatin and
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical …